CStone Pharma repurchases 1.33 million shares for HK$6.23 million, equal to 0.08% of share capital

Bulletin Express

Jun 16

CStone Pharmaceuticals (CStone Pharma) disclosed that it repurchased 1.33 million ordinary shares on 16 June 2026 via on-exchange transactions at prices between HK$4.61 and HK$4.74, for a total consideration of HK$6.23 million. The volume-weighted average price was about HK$4.68 per share.

Including 6,000 shares repurchased on 15 June 2026 at HK$4.66 each, the company now holds 1.34 million shares pending cancellation, equivalent to approximately 0.08% of its 1.60 billion issued shares.

The latest buyback utilises less than 1% of the 136.45 million-share mandate approved on 25 June 2025; cumulative purchases under this authority represent 0.10% of the share base at the mandate date.

Under Hong Kong listing rules, CStone Pharma is subject to a 30-day moratorium on new share issues or treasury share sales following the 16 June repurchase, restricting such activities until 16 July 2026.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.etasphere.com/news/1111241834"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1111241834\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1111241834?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-16 22:45","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1111241834","market":"us","top_or_hot":-1,"title":"CStone Pharma repurchases 1.33 million shares for HK$6.23 million, equal to 0.08% of share capital","media":"Bulletin Express","content":"<p>CStone Pharmaceuticals (CStone Pharma) disclosed that it repurchased 1.33 million ordinary shares on 16 June 2026 via on-exchange transactions at prices between HK$4.61 and HK$4.74, for a total consideration of HK$6.23 million. The volume-weighted average price was about HK$4.68 per share.</p>\n<p>Including 6,000 shares repurchased on 15 June 2026 at HK$4.66 each, the company now holds 1.34 million shares pending cancellation, equivalent to approximately 0.08% of its 1.60 billion issued shares.</p>\n<p>The latest buyback utilises less than 1% of the 136.45 million-share mandate approved on 25 June 2025; cumulative purchases under this authority represent 0.10% of the share base at the mandate date.</p>\n<p>Under Hong Kong listing rules, CStone Pharma is subject to a 30-day moratorium on new share issues or treasury share sales following the 16 June repurchase, restricting such activities until 16 July 2026.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>CStone Pharma repurchases 1.33 million shares for HK$6.23 million, equal to 0.08% of share capital</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCStone Pharma repurchases 1.33 million shares for HK$6.23 million, equal to 0.08% of share capital\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-06-16 22:45</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>CStone Pharmaceuticals (CStone Pharma) disclosed that it repurchased 1.33 million ordinary shares on 16 June 2026 via on-exchange transactions at prices between HK$4.61 and HK$4.74, for a total consideration of HK$6.23 million. The volume-weighted average price was about HK$4.68 per share.</p>\n<p>Including 6,000 shares repurchased on 15 June 2026 at HK$4.66 each, the company now holds 1.34 million shares pending cancellation, equivalent to approximately 0.08% of its 1.60 billion issued shares.</p>\n<p>The latest buyback utilises less than 1% of the 136.45 million-share mandate approved on 25 June 2025; cumulative purchases under this authority represent 0.10% of the share base at the mandate date.</p>\n<p>Under Hong Kong listing rules, CStone Pharma is subject to a 30-day moratorium on new share issues or treasury share sales following the 16 June repurchase, restricting such activities until 16 July 2026.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"02616","symbol_name":"基石药业-B","start_time":0,"source_url":"","article_id":"1111241834","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1111241834","pubTimestamp":1781621103,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"CStone Pharmaceuticals (CStone Pharma) disclosed that it repurchased 1.33 million ordinary shares on 16 June 2026 via on-exchange transactions at prices between HK$4.61 and HK$4.74, for a total...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"02616":"基石药业-B"},"translate_title":"基石药业623万港元回购133万股相当于股本0.08%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02616":1},"content_text":"CStone Pharmaceuticals (CStone Pharma) disclosed that it repurchased 1.33 million ordinary shares on 16 June 2026 via on-exchange transactions at prices between HK$4.61 and HK$4.74, for a total consideration of HK$6.23 million. The volume-weighted average price was about HK$4.68 per share.\nIncluding 6,000 shares repurchased on 15 June 2026 at HK$4.66 each, the company now holds 1.34 million shares pending cancellation, equivalent to approximately 0.08% of its 1.60 billion issued shares.\nThe latest buyback utilises less than 1% of the 136.45 million-share mandate approved on 25 June 2025; cumulative purchases under this authority represent 0.10% of the share base at the mandate date.\nUnder Hong Kong listing rules, CStone Pharma is subject to a 30-day moratorium on new share issues or treasury share sales following the 16 June repurchase, restricting such activities until 16 July 2026.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}